Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer

This study tests a new type of immune cell therapy — called CAR-NK cell therapy — for men with metastatic castration-resistant prostate cancer (a form of advanced prostate cancer that no longer responds to hormone therapy). The therapy uses engineered immune cells (natural killer cells) from a donor to target a protein called PSMA found on prostate cancer cells. **You may be eligible if...** - You have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) - Your testosterone levels are at castration level (very low) - Your cancer cells test positive for PSMA protein - Your cancer has continued to progress despite hormone therapy (rising PSA, new bone lesions, or measurable tumor growth) - You have at least 6 months life expectancy - Your physical performance is acceptable (ECOG 0–2) **You may NOT be eligible if...** - You have previously received other cell therapies (e.g., dendritic cells, CAR-T cells) - You have serious organ dysfunction or uncontrolled infections - You have brain metastases or other active cancers Talk to your doctor to see if this trial is right for you.